PwC and BIOTECanada invite Canada's Life Sciences and Biotechnology sectors to participate in the fourth Canadian Life Sciences Forecast.
The leading edge survey will gauge challenges and issues facing the Life Sciences and Biotechnology industry. The survey's results will be released in the Canadian Life Sciences Forecast 2013, in January 2013.
The report will provide a unique perspective on current issues, forecasted trends and implications for the Canadian Life Sciences and Biotechnology industry and will draw on survey responses from Canadian executives and stakeholders. If you are a member of the Life Sciences and Biotechnology industry, PwC and BIOTECanada invite you to participate in this important senior executive survey. The project's national launch will provide the results to the media and general public. All individual responses are completely confidential and will not be disclosed to any third party. Only aggregated data will be reported.
To participate in this year's survey, please click here.
New mobile information technologies, combined with innovative business models, offer consumers the promise of greater control over their health, more choice, better access and a decrease in overall costs.
We call this new paradigm intelligent healthcare, and it is primed for significant global growth, with benefits such as:
Download the September issue of mHealth Insights to find out how developers of "intelligent healthcare apps" can navigate the regulatory requirements, ensure clinical efficacy, determine payment structures—and leverage the abundant opportunities available in this area of growing market interest.
Health care companies are finding their own moments of truth where they engage in new thinking about their customers. Whether these moments are prompted by inspiration from other industries, competition, health reform, consumer demands or the bottom line, agile companies are changing the way they get to know their customers, moving beyond basic transactions and embracing their patients and members as consumers and customers.
MoneyTreeTM : Dollar drought
US venture capital funding for the life sciences sector, The MoneyTree life sciences sector includes the biotechnology and medical device and equipment industries. Investments in these industries fell 39% in dollars and 22% in number of deals during the second quarter of 2012 from the same quarter of last year, according to the MoneyTreeTM Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA) based on data provided by Thomson Reuters. Venture capitalists invested $1.4 billion in 174 life sciences deals, continuing a decline spanning four consecutive quarters.
October 3-4, Chateau Laurier, Quebec
BioContactQuébec 2012 is a biopharmaceutical partnership symposium gathering over 800 participants. This year more than 75 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, will be presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as cardiology, drug delivery systems and medical technologies. Senior representatives from presenting bioparmaceutical companies will also be available for one-on-one biopartnering sessions. To learn more about BioContactQuébec and register for this year’s symposium visit http://www.biocontact.qc.ca/.
October 1-3, 2012, Boston, MA
Building on the success of it’s first five years in Washington, DC, international MedTech executives with regulatory, reimbursement, business development, legal, IP, marketing, quality, compliance, and other key responsibilities will meet in Boston to attend AdvaMed 2012. Along with industry leaders, business development professionals, investors, policy-makers, members of the media, legal experts, consultants, distributors, and other important stakeholders will attend this international conference. Network, share insights, do business with, gain access to capital and learn at this industry event. PwC is a sponsor of AdvaMed and Brian Williams will lead a panel.
October 3-5, 2012, Washington, DC
Now in its seventh year, the rEVOLUTION Symposium has become the place to discuss the most important strategic problems facing pharma and biotech CSOs. Speakers will examine the organization and management of R&D to uncover new disruptive discovery and development models and assess the continued impact of pricing, reimbursement, regulation and globalization on the industry.
Pheonix Medical Device CEO Conference
October 11-14, 2012, Scottsdale, AZ
The nineteenth annual Phoenix Conference will provide an outstanding opportunity for top level executives from large healthcare and small venture-backed companies to discuss the key strategic issues facing our industry. PwC is a co-founder and sponsor of the conference.